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Abstract
Leigh syndrome (LS) is a rare progressive multi-system neurodegenerative disorder, the genetics of which is frequently
difficult to resolve. Rapid determination of the genetic etiology of LS in a 5-year-old girl facilitated inclusion in Edison
Pharmaceutical’s phase 2B clinical trial of EPI-743. SNP-arrays and high-coverage whole exome sequencing were performed
on the proband, both parents and three unaffected siblings. Subsequent multi-tissue targeted high-depth mitochondrial
sequencing was performed using custom long-range PCR amplicons. Tissue-specific mutant load was also assessed by
qPCR. Complex I was interrogated by spectrophotometric enzyme assays and Western Blot. No putatively causal mutations
were identified in nuclear-encoded genes. Analysis of low-coverage off-target mitochondrial reads revealed a previously
unreported mitochondrial mutation in the proband in MT-ND3 (m.10134C.A, p.Q26K), a Complex I mitochondrial gene
previously associated with LS. Targeted investigations demonstrated that this mutation was 1% heteroplasmic in the
mother’s blood and homoplasmic in the proband’s blood, fibroblasts, liver and muscle. Enzyme assays revealed decreased
Complex I activity. The identification of this novel LS MT-ND3 variant, the genomics of which was accomplished in less than
3.5 weeks, indicates that rapid genomic approaches may prove useful in time-sensitive cases with an unresolved genetic
diagnosis.
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LS can be caused by a heterogeneous array of mitochondrial or
nuclear genetic mutations that decrease aerobic energy production. Although the most prevalent LS mutations are associated
with Complex IV (cytochrome C oxidase complex; e.g. COX15,
SURF1) [OMIM 603646, OMIM 185620], Complex I subunit
mutations are also common. Damaging variants have been
identified in the mitochondrial genome encoded genes MTND1, MT-ND2, MT-ND3, MT-ND4, MT-ND5, MT-ND6 [3,4],
and ten nuclear encoded Complex I NADH-ubiquinone oxidoreductase (NDU) proteins [5]. LS is the most common clinical
presentation of a Complex I deficiency [6,7].
A clinical diagnosis of LS can be reached without knowledge of
the causal mutation, the identification of which, until recently, has

Introduction
Leigh syndrome (LS) is a rare progressive neurodegenerative
disorder that is characterised by early onset (typically infancy or
early childhood) and a combination of signs including muscular
hypotonia or spasticity, dystonia, nystagmus, psychomotor retardation and occasionally epilepsy [1]. LS patients may show rapid
loss of previously acquired skills, failure to thrive and feeding
difficulties, with survival generally measured in years [1,2].
Bilateral symmetrical lesions in the central nervous system,
particularly in the brain stem, thalamus, and spinal cord are
diagnostic, as are findings of lactic acidosis and a Magnetic
Resonance Spectroscopy (MRS) lactate peak [1].
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six individuals were generated within 96 hours of sample receipt.
Rapid sequencing (including on-instrument cluster generation) was
performed on the Illumina HiSeq 2500 in less than twenty-seven
hours.
Targeted Mitochondrial Sequencing. Three primers pairs
[9] were used to generate overlapping PCR products (each
,6,000 bp) that encompassed the entire mitochondrial genome.
PCR products from each member of the family were used to
create libraries compatible with MiSeq and Ion Torrent PGM
sequencing. MiSeq libraries were prepared from 1 ng of PCR
product using the Nextera XT library preparation kits, and
sequencing was performed using the MiSeq 300 cycle v2 kits as per
the manufacturer’s instructions including on-instrument cluster
generation. Ion Torrent libraries were prepared using 100 ng of
each product in combination with the Ion Xpress Plus Library Kit
for AB Library Builder. Library Fragments were clonally amplified
onto Ion Sphere particles by emulsion PCR using the Ion One
Touch Template Preparation kits, and sequenced on Ion Torrent
318 chips. In both cases libraries were pooled prior to sequencing
and results obtained within 24 hours of the initial PCR reactions.
Informatics Pipeline. SNP arrays were analysed with
Illumina BeadStudio, PLINK and a set of custom scripts. Exome
and targeted mitochondrial sequencing reads were aligned to the
reference human genome (hg19) using the Burrows-Wheeler
alignment (BWA) and down-stream processing of sequence data
was done with Picard v1.8, SAMtools v0.1.18 and the Genome
Analysis Toolkit (GATK) version 2.2.8. Variants (SNP and Indels)
were identified using GATK, following version four of the GATK
Best Practice Variant Detection guide. Variants were annotated
using Annovar with UCSC Known Genes models, and known
polymorphisms were identified using dbSNP135, 1000 genomes
and NHLBI exome project with minor allele frequencies recorded
from each dataset. Subsequent analysis and identification of
candidate variants was performed using an in-house workflow
incorporating the annotated variant data and pedigree information.

often been impractical due to the technical limitations and cost
associated with Sanger sequencing multiple nuclear and mitochondrial candidate genes. Here we present the case of a child
who required a definitive genetic diagnosis for inclusion in an
ongoing Edison Pharmaceutical Phase 2B clinical trial of EPI-743,
a para-benzoquinone that facilitates repletion of reduced intracellular glutathione and shows promise for LS patients. All ten LS
children participating in a recent Phase 2A EPI-743 study
exhibited reversal of disease progression regardless of genetic
determinant or disease severity [8]. To identify the causal genetic
variant responsible for LS in the proband we employed tiered set
genomic investigations across all six members of the immediate
family, including development of a targeted Nextera-based
mitochondrial DNA sequencing assay, which led to the discovery
a novel LS MT-ND3 mutation.

Patients and Methods
Case Report
The proband, a girl, is the youngest of four healthy children
born to unrelated and clinically unremarkable Australian parents
(Figure 1A). There were no antenatal or postnatal issues of note,
and early growth and development were normal. First concerns
were raised when the proband was approximately 4 years of age,
when it became apparent that she had lost her ability to jump and
had developed an abnormal gait. It was also noted at this time that
her speech development was delayed. The proband’s parents
stated that she was slower in acquiring new skills than her siblings
from an early age. Following an MRI/MRS of the brain under
general anaesthesia at 4.5 years of age her speech became more
difficult to understand, her mobility and balance worsened, and
her behaviour deteriorated. Formal cardiology, audiology and
ophthalmology assessments were normal.
The patient’s score on the Newcastle Paediatric Mitochondrial
Disease Scale for sections I-III was 17 (range 0–79). Diagnostic
investigations were consistent with LS. The brain MRI revealed
extensive signal abnormality involving putamen, and to a lesser
extent, the globus pallidus bilaterally and the cerebral peduncles
(Figure 1B). MRS also revealed elevated lactate in the basal
ganglia (data not shown), although blood and CSF lactate levels
were normal. Liver function enzymes were all within the normal
range. The muscle biopsy showed fat accumulation and slightly
increased subsarcolemmal mitochondrial aggregates. However
there were no ragged red fibres and COX/SDH immunohistochemical staining was normal. Histological studies on the liver
biopsy showed an increased glycogen content and mild biliary
ductular proliferation, but no fibrosis. Electron microscopy study
of the liver showed occasional moderately enlarged mitochondria
with paracrystalline and crystalline inclusions.

Spectrophotometric assays of the respiratory chain
enzyme activity
Spectrophotometric determinations of enzyme activity for all
respiratory chain enzymes from skeletal muscle and liver biopsies
were performed as described previously [10].

qPCR quantification of mutant load
PCR primers specific to the MT-ND3 (m.10134C.A) mutation, and to wild-type controls were designed and are available
upon request. Quantitative PCR was performed using SYBR
green dye and 1 Unit of Immolase DNA Polymerase (Bioline,
Alexandria, NSW, Australia), with a final concentration of
1.5 mM MgCl2, 500 pM of each primer, 2% DMSO and 1 M
betaine. PCR products were generated from 5 ng of genomic
DNA isolated (Qiamp DNA Mini kit) from the proband’s blood,
fibroblasts, muscle and liver, and from the blood of all other family
members. Standard curves were generated from ten-fold dilutions
of the mutant and wildtype amplicons inserted into pCR2.1TOPO
vector (Life Technologies). The cycle conditions used were: 95uC
for 12 minutes, (95uC for 10 s, 66uC for 15 s, 72uC for 10 s)635
cycles.

Genomics and Bioinformatics
High-density SNP Arrays & Exome Sequencing. This
research was approved by the Human Research Ethics Committees of the Children’s Hospital at Westmead and the University of
Queensland, and written consent was obtained from the parents
on behalf of themselves and their children (all children aged less
than 10 years), as approved by the Human Research Ethics
Committees. DNA was extracted from peripheral blood samples
from the patient, both parents and three unaffected siblings. Copy
number changes (e.g. large indels) and genomic rearrangements
were assessed using the Illumina HumanOmni2.5-8 Multi-Use
SNP arrays. Exome sequencing libraries were prepared with the
TruSeq DNA sample prep kit, and exome capture was performed
using the Nimblegen v3 Human EZ-Exome kits. Libraries from all
PLOS ONE | www.plosone.org

Western Blot
Tissue samples were lysed as previously described [11], and
whole cell lysates from fibroblasts (15 mg of protein), and from
muscle and liver (5 mg of protein), were separated by SDS-PAGE
2
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Figure 1. A m.10134C.A Leigh syndrome mutation. (A) Family pedigree with the LS patient annotated as a filled black circle. (B) T2 supraorbital MRI of the proband showing symmetrical bilateral cystic gliosis within the globus pallidus (orange arrows). (C) Graphical depiction of the
mitochondrial genome, annotated with the MT-ND3 LS mutation identified in this study (bottom left, highlighted with an asterisk) and three
previously described mutations (see text for references). (D) Western blot analysis of Complex I components, where CF and PF denote to control and
patient fibroblasts), CM and PM denote control and patient muscle biopsy samples, and CL and PL denote control and patient liver biopsy samples.
These data show a reduction of Complex I (CoI) protein levels in muscle, but no significant reduction in liver, consistent with the results shown in
Table 2. We also observed elevated Complex II (CoII) in patient fibroblasts and muscle, Complex III (CoIII) in patient fibroblasts and liver, and Complex
IV (CoIV) in patient liver, suggesting compensatory mitochondrial proliferation.
doi:10.1371/journal.pone.0104879.g001

2500 sequencing run, yielding a non-redundant depth of 69x with
96% of targeted bases covered at 18-fold or greater. Both an
unbiased genome-wide screen of all nuclear encoded genes and a
manual investigation of known nuclear-encoded mitochondrial
disease associated genes, however, failed to reveal any putatively
disease causing homozygous, compound heterozygous or de novo
mutations.
Taking advantage of the high-depth exome sequencing, we used
off-target mitochondrial genome sequencing reads to survey for
putative disease-causing variants and identified a low-coverage (6x)
m.10134C.A mutation that was unique to the proband. This
variant induces a p.Gln26Lys change in MT-ND3 (NADHubiquinone oxidoreductase chain 3), a gene that has previously
been
associated
with
LS
[12–14].
The
mutation
(NC_012920.1:m.10134C.A; ClinVar SCV000153651) was predicted to be damaging by SIFT with an annotation of
‘‘Deleterious’’ with a score of 23.800, and ‘‘Possibly damaging’’

on a 4–12% polyacrylamide gel. A PVDF membrane was probed
for 2 h at RT with 1:1,000 MitoProfile Total OXPHOS Human
WB Antibody Cocktail (ab110411, Abcam). Anti-mouse IgG HRP
(GE Healthcare) at 1:2,500 was used as the secondary antibody.
Membranes were developed with ECL and exposed on Hyperfilm.
Films were scanned on a Microtek ScanMaker 8700 and analysed
using ImageQuant (GE Healthcare).

Results
In this case of a patient with typical LS features we undertook a
tiered investigation of increasing resolution that consisted of (i)
high-density SNP arrays, (ii) exome sequencing, (iii) targeted ultradeep mitochondrial sequencing on two different platforms, and (iv)
targeted multi-tissue sequencing. Analysis of the SNP array data
revealed no potentially pathogenic copy number or genomic
rearrangements. Exome sequencing was performed at high depth a total of 71 gigabases were generated from a single rapid HiSeq
PLOS ONE | www.plosone.org
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To resolve the genetics underpinning LS in this case we
employed a tiered investigation using technologies of increasing
resolution that resulted in the identification of a novel mutation in
MT-ND3 (m.10134C.A, p.Gln26Lys), which facilitated patient
inclusion into the phase 2B clinical trial of EPI-743. The SNP
arrays, exome and targeted mitochondrial ultra-deep sequencing
were completed in less than three and a half weeks, a timeframe
comparable to commercially available single gene diagnostic tests.
Other orthogonal approaches may have resolved the case in a
similar timeframe (e.g. Sanger sequencing of the mitochondrial
genome partnered with targeted nuclear gene investigations), but
we note that the approach used here provided both maximum
depth and breadth and therefore the highest likelihood of causal
mutation detection. Access to genetic material from all members of
the immediate family virtually eliminated all false positives.
Amongst nuclear encoded genes we found only one putative
de novo mutation, and no homozygous or compound heterozygous mutations that segregated with the proband, thus reducing
the overall period of the investigation.
PLOS ONE | www.plosone.org
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Table 1. Targeted mitochondrial next-generation sequencing.

Discussion

15

Indel

by PolyPhen2 with a score of 0.611 [15,16]. The m.10134C.A
variant is not recorded in dbSNP, was absent from the mtDB
database, which lists mtDNA variants in 2704 sequenced mtDNA
genomes [17], and was not detected in any of over 300 control
exomes previously sequenced by our group.
We performed targeted ultra-deep mitochondrial investigations
of the m.10134C.A mutation on the both the MiSeq (,20,000fold) and the Ion Torrent (,5,000-fold), which revealed that the
father and all three unaffected siblings carried only the wild-type
allele, and that both the proband and the mother carried the
m.10134C.A allele at levels of ,99.9% and 1% respectively
(Table 1). These data strongly indicated that the p.Gln26Lys
nonsynonymous MT-ND3 change was likely to be the cause of LS
in this patient.
To assess the functional consequences of the m.10134C.A
(p.Gln26Lys) mutation on MT-ND3, spectrophotometric enzyme
assays of Complex I were performed, which revealed that
Complex I was 24%, 17% and 13% of normal relative to protein,
citrate synthase and Complex II, respectively, in patient skeletal
muscle; and that Complex I was low relative to CS (50%) and
Complex II (34%), but normal relative to protein in liver.
Additionally, Complex II, citrate synthase and Complex IV
activities were elevated in both muscle and liver, and Complex III
was elevated in liver (Table 2), suggesting some degree of
compensatory mitochondrial proliferation. Analysis by Western
blot mirrored the enzyme assay results, showing a reduction in
Complex I protein levels in muscle, but normal levels in liver
(Figure 1D).
To investigate the tissue-specific load of the m.10134C.A
mutation in the proband, ultra-deep targeted MiSeq sequencing
and qPCR of DNA from muscle, liver and fibroblasts was
performed. Sequencing revealed homoplasmy for the mutation in
all tissues tested (Table 1), which was confirmed by qPCR. This
suggests that the differences in relative Complex I activity in
muscle and liver are not the result of developmental mitochondrial
mosaicism, and may simply reflect patient- and tissue-specific
variability on the impact of the mutation on complex I enzyme
activity, as noted for another MT-ND3 mutation, m.10191T.C
[13]. These data also highlight the fact that homoplasmic
mitochondrial mutations are not by definition embryonic lethal,
and may have variable and tissue-specific consequences which are
likely to be tied to background genetics (see below).

-
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Table 2. Muscle and liver respiratory chain enzyme activity.

Ref Range

Activity (%)

% CS Ratio

% CII ratio

Muscle
Complex I (nmol/min/mg)

(19–72)

10 (24)

17

13

Complex II (nmol/min/mg)

(26–63)

81 (180)

123

-

Complex III (/min/mg)

(12.8–50.9)

40.5 (139)

92

76

Complex IV (/min/mg)

(3.3–9.1)

19.8 (300)

209

170

Citrate Synthase (nmol/min/mg)

(85–179)

187 (145)

-

-

Liver
Complex I (nmol/min/mg)

(8–11)

7 (74)

50

34

Complex II (nmol/min/mg)

(54–73)

134 (220)

147

-

Complex III (/min/mg)

(5.2–10.3)

23.7 (312)

208

143

Complex IV (/min/mg)

(0.5–0.9)

2.44 (344)

233

157

Citrate Synthase (nmol/min/mg)

(26–31)

41 (146)

-

-

Note: Bold characters indicate diagnostically abnormal values. Complex I, NADH-coenzyme Q1 oxidoreductase; Complex II, succinate-coenzyme Q1 oxidoreductase;
Complex III, decylbenzylquinol-cytochrome c oxidoreductase; Complex IV, cytochrome c oxidase. Data are expressed as a ratio relative to citrate synthase (% CS ratio)
and Complex II activity (% CII ratio).
doi:10.1371/journal.pone.0104879.t002

Three other LS MT-ND3 mutations have been reported m.10158T.C, m.10191T.C, m.10197G.A [12–14] - and may
shed light on some of the results described here. For example, a
recent meta-analysis of patients carrying the m.10191T.C
mutation demonstrated that there is no clear correlation between
mutant load and Complex I activity in muscle and liver [3]. This is
consistent with the observed marked decrease in Complex I
activity in muscle, but little overall reduction in liver, despite the
fact that both tissues are homoplasmic by both qPCR and targeted
next-generation sequencing for the m.10134C.A mutation. The
biology underpinning such tissue specific variation in enzyme
activities and compensatory responses is unresolved, but is likely to
be linked to the mutation’s affect on MT-ND3 activity in the
context of a specific molecular background. Indeed, prior work
investigating m.10191T.C has shown a reduction in Complex I
catalytic activity [13], which is consistent with the results presented
here that show a reduction in enzyme activity (Table 2) while
protein levels are relatively unaffected (Figure 1D). Higher
residual activity of Complex I in liver compared with muscle is
not unique to MT-ND3 mutations. We have found similar
differences with residual activity of Complex I being 2- to 5-fold
higher in liver than muscle for patients with near-homoplasmic
MT-ND6 mutations and in patients with autosomal recessive
mutations in the NDUFS6, NDUFS8 and NDUFV1 Complex I
subunit genes (unpublished data). Similarly, there does not appear
to be a simple correlation as to why Complex I subunit mutations
appear to induce mitochondrial proliferation in some tissues and
patients but not others. While it would be interesting to study
markers of mitochondrial biogenesis in patient biopsies, this is
usually impractical due to the limitation in size of biopsies, at least
for paediatric patients.
The clinical utility of an un-constrained high-throughput
sequencing approach, particularly in cases with an unresolved
diagnosis, is now clearly established. It is also evident, that the
approaches used in such cases must be largely free of systematic
biases. We note that in our study that the m.10134C.A mutation
created a four base adenine homopolymer (Figure 1C) that
resulted in a 27% indel call rate in the proband’s Ion Torrent
PLOS ONE | www.plosone.org

targeted sequencing data, and masked the low-level mutation in
the maternal sample (Table 1). This highlights the need for
multiple validated and orthogonal sequencing approaches in
clinical and diagnostic investigations.
We note that identification of the causal mutation in the
proband was successful despite the initial dependence on lowcoverage off-target mitochondrial sequencing reads, and potential
issues stemming from nuclear copies of mitochondrial DNA
(NUMTs), suggesting that next-generation sequencing approaches
may be particularly useful in the diagnosis of mitochondrial
disorders. This is likely to be particularly true if more targeted, e.g.
directed mtDNA sequencing, or broader approaches, e.g. whole
genome sequencing (WGS), as opposed to WES, are employed.
Indeed, although WGS is currently cost-prohibitive for most
research and diagnostic investigations, its use would have
dramatically reduced the time required to resolve this case. Whole
genome sequencing libraries can be generated in less than 24
hours, and running all six family members would have taken a
little more than a week and yielded at least 1,000x coverage of the
mitochondrial genome. We anticipate that as sequencing costs
continue to fall the utility of WGS for resolution of genetically
mediated mitochondrial disease will increase. Consistent with
previous reports [18–20], in this case we observed ultra-low level
maternal heteroplasmy of the m.10134C.A mutation and
homoplasmy in the proband, underscoring the importance of
using high-throughput strategies for mitochondrial disease gene
identification in apparently sporadic cases.
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